-transparent.png){kind=logo}
The cost of biologic therapies adds urgency to the need to develop realistic compliance strategies. By engaging and educating both the physician and patient, some MCOs are working hard to address at what has always been a complicated and formidable issue.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Scott Kober
January 1987,
The Western journal of medicine,
Scott Kober
September 1999,
BMJ (Clinical research ed.),
Scott Kober
March 1996,
The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses,
Scott Kober
January 2008,
Nursing standard (Royal College of Nursing (Great Britain) : 1987),
Scott Kober
October 1987,
Nursing standard (Royal College of Nursing (Great Britain) : 1987),
